Skip to content

Clinical efficacy and mechanism of Yinlian Yueju Formula in the treatment of metabolism-related fatty liver disease

Clinical efficacy and mechanism of Yinlian Yueju Formula in the treatment of metabolism-related fatty liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001135
Enrollment
Unknown
Registered
2025-06-07
Start date
2022-03-10
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic dysfunction associated fatty liver disease

Interventions

control subjects:Placebo pellets + regulated diet and exercise and guideline-referenced management of blood pressure lipids and blood glucose
test group:Yinlian Yueju Granules + standardised diet and exercise and guideline-based management of blood pressure lipids and blood glucose

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 Those who meet the diagnostic criteria of metabolism-related fatty liver disease in Chinese and western medicine; 2 Age =18 years and =65 years gender is not limited; 3 Understand agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1 Alcohol consumption equivalent to ethanol >140g per week (equivalent to 2.5 taels of 56-degree white wine) for men and >70g per week (equivalent to 1.25 taels of 56-degree white wine) for women; and alcohol consumption for >5 years; 2 Patients with viral hepatitis drug-induced liver disease total parenteral nutrition and hepatomegaly; 3 those who add other herbal liver protection and enzyme-lowering drugs (e.g. Yi Liver Ling Liver Protecting Tablets Dang Fei Li Liver Ning Capsules etc.) and the time of discontinuation is 3 x ULN and creatinine (Cr) >1.5 x ULN; 9 Patients who are allergic to Yinlian Yueju Granules or the constituents thereof.

Design outcomes

Primary

MeasureTime frame
controlled attenuation parameter;

Secondary

MeasureTime frame
Arrhythmic gene;Lipids;C - reactive protein;Liver Function Indicators;Glycaemic indicators;Body Mass Index;Blood Pressure;Insulin Resistance Index;Chinese Medicine Symptom Score;

Countries

China

Contacts

Public ContactXiaoli He

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine Shanghai China

fishstata@163.com+86 18621835178

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026